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Abstract: AIMS Various studies have attempted to identify super-responders to cardiac resynchroniza-
tion therapy (CRT) by echocardiographic parameters of reverse remodeling. However, scientific evidence
regarding those parameters is scarce. This study aimed at validating the definition of super-response to
CRT based on the following frequently employed echocardiographic parameters: left ventricular ejection
fraction (LVEF), end-diastolic volume index (EDVI), and end-systolic volume index (ESVI). METHODS
AND RESULTS We retrospectively investigated echocardiographic data and outcomes of 542 patients
after CRT implantation. The primary endpoint comprised all-cause mortality, heart transplantation,
ventricular assist device implantation (VAD), and hospitalization for heart failure. Secondary endpoints
were hospitalization for heart failure, and the combination of all-cause mortality, heart transplantation
and VAD. Two approaches were employed defining super-response based on improvement of echocardio-
graphic parameters: one derived from the negative predictive value (NPV) for clinical endpoints, and
second from best quartiles of improvement. Using the NPV method, an absolute 25 % increase in LVEF,
a relative 38 % reduction in EDVI, and 46 % in ESVI were calculated as optimal cut-offs identifying
4.9, 18.5, and 21.3 % as super-responders. The best quartiles method resulted in lower cut-off values,
i.e. 14 % increase in LVEF, 26 % reduction in EDVI, and 36 % in ESVI. All cut-offs except LVEF
฀25% were significantly associated with improved outcomes after 5 years (median follow-up 35.7 months).
CONCLUSIONS NPV- and best quartile-based cut-offs validate previously applied empirical echocardio-
graphic cut-offs to define super-response to CRT. These data provide evidence for using these empirical
cut-offs in daily practice and facilitate inter-study comparability.
DOI: https://doi.org/10.1007/s00392-014-0763-6





Hürlimann, David; Schmidt, Susann; Seifert, Burkhardt; Saguner, Ardan M; Hindricks, Gerhard; Lüscher,
Thomas F; Ruschitzka, Frank; Steffel, Jan (2015). Outcome of super-responders to cardiac resynchro-
nization therapy defined by endpoint-derived parameters of left ventricular remodeling: A two-center
retrospective study. Clinical Research in Cardiology, 104(2):136-144.
DOI: https://doi.org/10.1007/s00392-014-0763-6
ORIGINAL PAPER
Outcome of super-responders to cardiac resynchronization
therapy defined by endpoint-derived parameters of left
ventricular remodeling: a two-center retrospective study
David Hürlimann • Susann Schmidt • Burkhardt Seifert •
Ardan M. Saguner • Gerhard Hindricks • Thomas F. Lüscher •
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Abstract
Aims Various studies have attempted to identify super-
responders to cardiac resynchronization therapy (CRT) by
echocardiographic parameters of reverse remodeling.
However, scientific evidence regarding those parameters is
scarce. This study aimed at validating the definition of
super-response to CRT based on the following frequently
employed echocardiographic parameters: left ventricular
ejection fraction (LVEF), end-diastolic volume index
(EDVI), and end-systolic volume index (ESVI).
Methods and results We retrospectively investigated
echocardiographic data and outcomes of 542 patients after
CRT implantation. The primary endpoint comprised all-
cause mortality, heart transplantation, ventricular assist
device implantation (VAD), and hospitalization for heart
failure. Secondary endpoints were hospitalization for heart
failure, and the combination of all-cause mortality, heart
transplantation and VAD. Two approaches were employed
defining super-response based on improvement of echo-
cardiographic parameters: one derived from the negative
predictive value (NPV) for clinical endpoints, and second
from best quartiles of improvement. Using the NPV
method, an absolute 25 % increase in LVEF, a relative
38 % reduction in EDVI, and 46 % in ESVI were calcu-
lated as optimal cut-offs identifying 4.9, 18.5, and 21.3 %
as super-responders. The best quartiles method resulted in
lower cut-off values, i.e. 14 % increase in LVEF, 26 %
reduction in EDVI, and 36 % in ESVI. All cut-offs except
LVEF C25% were significantly associated with improved
outcomes after 5 years (median follow-up 35.7 months).
Conclusions NPV- and best quartile-based cut-offs vali-
date previously applied empirical echocardiographic cut-
offs to define super-response to CRT. These data provide
evidence for using these empirical cut-offs in daily practice
and facilitate inter-study comparability.
Keywords Cardiac resynchronization therapy  Cardiac
failure  Super-responder  Cardiac devices  CRT device 
Left ventricular remodeling
Introduction
Cardiac resynchronization therapy (CRT) has become a
cornerstone in the treatment of patients with symptomatic
heart failure, LV ejection fraction B35 % and a prolonged
QRS duration (C120 ms) despite optimal medical therapy
[1, 2]. However, the response rate to CRT may vary con-
siderably among patients. Some patients, typically referred
to as ‘‘super-responders’’, show striking reverse remodeling
and an increase or even normalization of ejection fraction
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or chamber size. The proportion of super-responders is
reported to be in the range of 12–47 % of patients under-
going CRT implantation. [3–10].
The lack of a universal definition of super-response to
CRT is one of the main reasons for the wide range of
percentages observed in these studies. A number of
investigations attempted to identify super-responders
focusing on various echocardiographic parameters of
reverse remodeling. Yu et al. [11], Ypenburg [6] and Poller
[12] defined super-responder by an improvement in left
ventricular end-systolic volume (LVESV), although dif-
ferent cut-offs were selected [6, 11]. Another study group
used vectorcardiography parameters to assess response to
CRT [13]. We have previously compared three definitions
for super-responders defined by an absolute increase in
LVEF C10 %, a decrease in end-systolic volume index
(ESVI) by C30 % and end-diastolic volume index (EDVI)
by C20 %, and found that either of these cut-off points are
highly predictive for clinical improvement and survival
after CRT implantation [3].
Common to all above-mentioned studies (including our
previous work), however, was that both the parameters as
well as the individual cut-offs used for defining super-
response to CRT were more or less arbitrarily chosen, pri-
marily based on previously published studies rather than
endpoint-derived evidence. The aim of the current study,
therefore, was to comprehensively determine cut-off values
for three commonly used parameters defining echocardio-
graphic super-response (improvement in LVEF, EDVI,
ESVI), and to compare them among each other as well as
with previously employed, empirically derived cut-off values.
Methods
Study population
All patients (n = 542) receiving a de novo CRT implan-
tation or CRT upgrade at the University Heart Center
Zurich (n = 182) or at the Heart Center Leipzig (n = 360)
between November 2000 and December 2012, in whom an
echocardiogram between 1 and 30 months after implanta-
tion was available were included in the study. In rare cases,
where no echocardiogram was performed, available data
from magnetic resonance tomography or levocardiography
were used. Overall, 823 patients had to be excluded due to
incomplete or missing follow-up. Patients received devices
and leads from Biotronik, Boston Scientific, Medtronic and
St. Jude Medical (Table 1). The standard approach for LV
lead positioning was via a transvenous access through the
coronary sinus into either a posterolateral or lateral vein. If
transvenous implantation was not possible, epicardial lead
implantation was performed (30 patients, 5.5 %). Data on
the clinical follow-up were retrieved from hospital records,
as well as through contact with the patients’ general
practitioners, external cardiologists and the patients them-
selves. This retrospective study was approved by the ethics
committee of the University of Zurich (KEK-ZH-Nr.
2011-0304) and the Institutional Review Board of the
Heart Center Leipzig.
Endpoints and statistics
The primary endpoint of the study was the combined
endpoint of all-cause mortality, heart transplantation,
Table 1 Baseline characteristics
Mean ± SD
Clinical
Men (%) 432/542 (79.9)
Age at implantation (years) 64.7 ± 11.0
Heart rate (bpm) 75.0 ± 18.3
nt-pro BNP (pg/ml) 4,314 (140–55,053)*
Coronary artery disease-n (%) 432/542 (79.9)
QRS duration (msec) 148.6 ± 34.6
Atrial fibrillation-n (%) 104/542 (19.2)
Time diagnosis-implantation (months) 48.4 ± 68.5
Echocardiography at time of CRT implantation
End-diastolic volume index (EDVI)
(ml/m2)
106.9 ± 39.8
End-systolic volume index (ESVI) (ml/m2) 79.5 ± 35.4
Left ventricular ejection fraction
(LVEF) (%)
26.0 ± 8.4
RV/RA gradient 38.0 ± 13.2
Right ventricular fractional area change
(%)
41.7 ± 13.8
Tricuspid annulus motion (TAM) (mm) 16.6 ± 5.8
Interventricular mechanical delay (msec) 37.5 ± 34.7
Echocardiography post implantation
Time FU echo from implant (months) 9.0 ± 4.1
End-diastolic volume index (ml/m2) 97.7 ± 36.4
Delta EDVI (ml/m2) -8.3 (-73.8–162.1)*
End-systolic volume index (ml/m2) 68.2 ± 36.4
Delta ESVI (ml/m2) -13.8
(-77.2–413.5)*
LVEF (%) 32.7 ± 11.2
Delta LVEF (%) 6.6 ± 10.4
Manufacturer devices
Biotronik (%) 114 (21.0)
Medtronic (%) 112 (20.7)
St. Jude Medical (%)l 298 (55.0)
Boston Scientific (%) 18 (3.3)
Categorical data are presented as number of patients (%), continuous
data as mean (±SD) unless indicated. Asterisk median (range)
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ventricular assist device implantation and hospitalization
for heart failure. Additionally we evaluated hospitaliza-
tion for heart failure as well as the combination of all-
cause mortality, heart transplantation and ventricular
assist device (VAD) implantation as secondary endpoints.
Freedom from endpoints was assessed during 5 years
from CRT implantation and was computed using Kap-
lan–Meier analysis with delayed entry at the time of
echocardiography. Differences in survival curves between
super-responders and non-responders were computed with
the log-rank test using Stata 11.2 (Stata Corp, College
Station, Texas, USA). All other calculations and graphics
were performed using R Statistical Software (Foundation
for Statistical Computing, Vienna, Austria). A p value of
\0.05 was considered statistically significant.
Assessment of super-response
To determine the most useful parameter among LVEF,
EDVI, and ESVI, the percentage change of each parameter
(Delta LVEF, Delta EDVI, Delta ESVI) from baseline to
first follow-up was computed. To determine cut-off values
for defining a super-responder status after CRT implanta-
tion, two methods were applied.
Determination of super-responders based on negative
predictive value
In contrast to the method based on best quartile, cut-offs
for left ventricular remodeling were based on the nega-
tive predictive value (NPV), i.e. the probability of 5-year
freedom from the primary endpoint for patients classified
as super-responder. The package ‘survivalROC’ [14] was
used first to compute sensitivity and specificity as a
function of the cut-off value. The negative predictive
value was then obtained using Bayes formula and plotted
as a function of the left ventricular improvement. The
cut-off for super-response was the value, which defined
as many patients as possible with a NPV of at least
75 %. To evaluate the prognostic performance of
parameters of left ventricular remodeling, ROC curves
were plotted, the areas under the curves were computed,
and sensitivities and specificities of super-responder
definitions calculated. Afterwards freedom from end-
points was illustrated using Kaplan–Meier curves as
described above.
Determination of super-response based on best quartile
In the ‘‘best quartile’’ method, super-response was defined
by the top quartile of LVEF, EDVI or ESVI improvement,
regardless of the patients’ clinical outcomes.
Results
Baseline characteristics and follow-up
The patients‘ baseline characteristics including echocardio-
graphic and electrocardiographic parameters are given in
Table 1. 345 (63.7 %) patients received a new CRT device,
118 (21.8 %) a pacemaker upgrade and 79 (14.6 %) an ICD
upgrade. All patients were on optimal heart failure therapy at
the time of implantation: 481 patients (88.7 %) were on
angiotensin-converting enzyme inhibitors or angiotensin
receptor antagonists, 463 (85.0 %) on beta blockers, 418
(77.1 %) on loop diuretics, 171 (31.5 %) on thiazides, 300
(55.4 %) on spironolactone, 70 (12.8 %) on nitrates, 36
(6.6 %) on calcium antagonists, 291 (53.7 %) on lipid lower-
ing treatment, and 78 (14.4 %) patients were on amiodarone.
Mean follow-up was 35.7 ± 24.7 months (range
0.3–115.4 months). During this time, 248 patients (45.8 %)
reached the combined endpoint, which included 160 deaths
(29.5 %), 12 heart transplantations (2.2 %), 12 left ven-
tricular assist device implantations (2.2 %), and 173 hos-
pitalizations for heart failure (21.4 %, Table 2).
The mean time of echocardiographic follow-up was
9.0 ± 4.1 months. LVEF increased after CRT from
26.1 ± 8.5 to 32.7 ± 11.7 %. Accordingly, ESVI and
EDVI decreased from 79.5 ± 35.4 to 68.2 ± 36.4 ml/m2
and 106.9 ± 39.8 to 97.7 ± 41.2 ml/m2, respectively.
Determination of super-responder status based
on the NPV
Using the NPV-based method, an absolute increase in
LVEF by 25 %, a reduction in EDVI by 38 %, and a
reduction in ESVI by 46 % were calculated as the optimal
cut-off values to define super-response (Fig. 1). These
definitions yielded a NPV of 75 % and identified 4.9 %
(22/452), 18.5 % (58/314) and 21.3 % (66/310) of patients,
respectively, as super-responders. There was no relevant
difference in the AUC between each parameter. The AUC
for all parameters were considered useful at separating
between the outcome of super-responders and non-super-
responders (Delta LVEF AUC 0.67[ Delta ESVI AUC
Table 2 Follow-up and endpoints
Follow-up (months) 35.7 ± 24.7
Combined endpoint 248 (45.8 %)
Death 160 (29.5 %)
Heart transplantation 12 (2.2 %)
Ventricular assist device 12 (2.2 %)
Congestive heart failure hospitalization 173 (31.9 %)
Data are presented as mean (±SD) and number of patients (%) for
continuous and categorical variables, respectively
138 Clin Res Cardiol (2015) 104:136–144
123
0.65[Delta EDVI 0.61). Super-responders as defined by a
relative decrease of EDVI C38 % and ESVI C47 % were
significantly less likely to reach the combined primary, as
well as the secondary endpoints (Tables 3, 4, 5). In con-
trast, the cut-off value for LVEF improvement C25 % was
not associated with a reduced probability of death, heart
transplantation and implantation of a left ventricular assist
device (p = 0.072.). The corresponding Kaplan–Meier
estimates of event-free survival are shown in Fig. 2.
Determination of super-responder definition based
on the best quartile
Using the method based on the best quartile, super-
response was defined by an absolute improvement in LVEF
of 14 %, a relative improvement in EDVI by 25 % or a
relative improvement in ESVI by 36 %. Using these defi-
nitions, 133/337 (39.5 %), 104/255 (40.8 %) and 101/271
(37.3 %) of patients, respectively, were classified as super-
responders (Tables 3, 4, 5). With this method, significant
results were obtained regarding 5-years freedom from both
the primary and secondary endpoints for all parameters and
cut-offs investigated. The corresponding Kaplan–Meier
estimates of event-free survival are illustrated in Fig. 3.
Discussion
We here for the first time used an objective approach to
assess the optimal parameter and its cut-off point using an
NPV-based analysis to determine whether different echo-
cardiographic parameters of left ventricular remodeling
based on clinical outcome data, rather than empiric values,
may precisely predict super-response to CRT.
In our previous work [3], as well as in other studies, cut-
off-points for all echocardiographic parameters were
determined a priori, followed by outcome analysis to
evaluate the influence of echocardiographic response on
the clinical course [3]. The somewhat arbitrary determi-
nation of cut-off values is frequently problematic due to
several reasons. First, there is no consensus regarding
which echocardiographic parameter is most appropriate
with a good reproducibility in daily clinical practice. Sec-
ond, most of the cut-off points which were chosen in pre-
vious projects were empirically derived and predetermined
[3–6, 8, 9, 11].
Our current study was undertaken to address these two
shortcomings. Indeed, we were able to identify endpoint-
derived cut-off values for the most frequently employed
markers of LV remodeling.
Fig. 1 NPV-based method. Upper panel: determination of optimal cut-off point for the definition of super-response. Lower panel: ROC curves
(Delta LVEF, Delta EDVI, Delta ESVI). point NPV-based cut-off point, cross best quartile-based cut-off point
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End-diastolic volume index
An improvement in EDVI may represent an important
parameter when it comes to evaluating the response to
CRT, as it reflects true reverse remodeling (i.e. a genuine
reduction in left ventricular size). Celib et al. classified 22
out of 136 CRT patients (16.2 %) with a 27 % LVEDD
reduction after an average follow-up of 9.4 months as
Table 3 Outcome of super-
responders according to
improvement in delta LVEF
NPV-based cut-off LVEF 25 % Best quartile-based cut-off LVEF 14 %
D LVEF
Specificity (%) 6.9 30.6
Sensitivity (%) 97.9 86.6
Super-responder Non super-responder Super-responder Non super-responder
Combined endpoint
n 27 447 119 351
5-years freedom (%) 75.6 43.3 72.2 36.0
CI 0.57–1.0 0.37–0.5 0.63–0.83 0.30–0.44
p value 0.033 \0.0001
Death/heart transplantation/LVAD
n 29 506 129 406
5-years freedom (%) 81.6 48.1 78.2 41.3
CI 0.67–1.0 0.42–0.56 0.70–0.87 0.35–0.49
p value 0.072 \0.0001
CHF hospitalization
n 27 443 119 351
5-years freedom (%) 90.0 64.2 83.6 59.0
CI 0.73–1.0 0.58–0.71 0.76–0.93 0.52–0.67
p value 0.037 0.0001
Table 4 Outcome of super-
responders according to
improvement in delta EDVI
NPV-based cut-off EDVI 38 % Best quartile-based cut-off EDVI 26 %
D EDVI
Specificity (%) 21.7 34.4
Sensitivity (%) 91.5 82.5
Super-responder Non super-responder Super-responder Non super-responder
Combined endpoint
n 56 316 99 270
5-years freedom (%) 76.1 39.8 68.5 36.8
CI 0.64–0.91 0.33–0.48 0.58–0.81 0.30–0.45
p value 0.032 0.008
Death/heart transplantation/LVAD
n 57 356 104 309
5-years freedom (%) 84.3 44.4 75.7 41.9
CI 0.74–0.96 0.37–0.53 0.66–0.87 0.35–0.51
p value 0.0099 0.017
CHF hospitalization
n 56 313 99 270
5-years freedom (%) 89.7 59.5 90.0 54.7
CI 0.81–1.0 0.52–0.68 0.83–0.97 0.47–0.64
p value 0.019 0.0001
140 Clin Res Cardiol (2015) 104:136–144
123
super-responders. Although patients were classified as
super-responders with a LVEDD reduction beyond the 80th
percentile, the latter was based on hypothesis rather than
endpoint analysis [8].
Both of our methods measured higher cut-off values for
relative decreases in EDVI than in our previous study
(20 %) [3]. The NPV-based method with a higher cut-off
point identified fewer patients as super-responders. Con-
versely, freedom from the combined endpoint, death/heart
transplantation/left ventricular assist device, and hospital-
ization due to heart failure was slightly higher using the
NPV- versus best quartile-based cut-off point.
End-systolic volume index
Improvements in ESVI have more often been employed
than EDVI for identifying super-response after cardiac
resynchronization therapy, and a link between improve-
ment in ESVI and a survival benefit has frequently been
postulated [11, 15, 16] [4, 6, 11, 17]. Similar to the other
definitions, we received higher cut-off values for ESVI
than previous studies. The associated AUC for cardiovas-
cular mortality was 0.774, which is similar to the data from
Yu et al. [11].
We obtained a threshold of ESVI improvement of 46 %
with the NPV-based analysis and 36 % with the best
quartile-based method. Comparing both methods, the per-
centage of super-responders for freedom from the
combined endpoint, from death, heart transplantation and
LVAD implantation, as well as freedom from CHF hos-
pitalization was always higher using the NPV-based
method as compared to the best quartile-based method,
implying that the NPV-based method may be more capable
in better identifying super-responders. However, the
absolute number of super-responders was lower using the
NPV-based method, resulting in a higher number of
patients with a favorable clinical outcome who did not
qualify as ‘‘super-responders’’ per this definition. As
expected, a reduced absolute number of super-responders
were identified with increasing absolute cut-off values.
Left ventricular ejection fraction
The best quartile-based cut-off for LVEF improvement
(14 %) turned out to be identical to the one recently chosen
for the analysis of MADIT-CRT (14 %) [7]. This may have
been due to a similar approach for identification of super-
responders using the top quartile of LVEF change. The
concordance of both studies hence strongly indicates a high
degree of reproducibility and, consequently, reliability of
the received cut-off point.
In our previous study, 47 % patients were identified as
super-responders as defined by an absolute increase in
LVEF C10 %, which reached statistical significance for
freedom from the combined endpoint and hospitalization,
but not for freedom from all-cause mortality. Likewise, our
Table 5 Outcome of super-
responders according to
improvement in delta ESVI
NPV-based cut-off ESVI 47 % Best quartile-based cut-off ESVI 36 %
D ESVI
Specificity (%) 23.9 34.5
Sensitivity (%) 90.8 83.2
Super-responder Non super-responder Super-responder Non super-responder
Combined endpoint
n 65 311 101 271
5-years freedom (%) 75.1 39.2 68.5 36.9
CI 0.64–0.89 0.33–0.47 0.58–0.80 0.3–0.46
p value \0.0001 \0.0001
Death/heart transplantation/LVAD
n 68 349 106 311
5-years freedom (%) 84.1 43.5 76.3 41.8
CI 0.75–0.95 0.36–0.52 0.67–0.87 0.35–0.51
p value \0.0001 \0.0001
CHF hospitalization
n 65 307 101 271
5-years freedom (%) 89.0 58.6 87.0 55.7
CI 0.80–0.99 0.51–0.67 0.79–0.96 0.48–0.64
p value 0.0001 \0.0001
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present study demonstrates a significant reduction of all
endpoints with both cut-off points, except for LVEF
C25 % for the combined secondary mortality endpoint [3].
When comparing the NPV-based (C25 %) with the best
quartile-based threshold (C14 %), we obtained fewer
super-responders with the former due to the higher cut-off
point. The fact that an improvement in LVEF of C25 %
was not associated with a statistically significant reduction
in the combined secondary endpoint may be due to the
substantially lower specificity for the NPV-based cut-off
(6.9 vs. 30.6 %), indicating that some patients with a
pronounced response did not qualify as super-responders as
per the NPV-based definition. Instead, this threshold
clearly identified very pronounced super-responders
regarding the hospitalization for the secondary endpoint
heart failure, with only a few events occurring until
50 months after CRT implantation.
Limitations
This is a retrospective study, limited to patients who
were followed-up at two large-scale tertiary care centers
with mid-term follow-up to assess reverse remodeling.
As a result, several patients who were implanted were
not included in the analysis due to lack of follow-up data
(external referrals etc.). These aspects, however, are
Fig. 2 NPV-based method: probability of freedom from the com-
bined endpoint (upper), death/heart transplantation/ventricular assist
device (middle) and hospitalization for heart failure (lower panel) for
different definitions of super-responders: D LVEF[25 % (left); D
EDVI\38 % (middle); and D ESVI\46 % (right panel)
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inherent limitations of any ‘‘real world’’ investigation;
conversely, they are potentially outweighed by the fact
that patients were consecutively included without any
pre-selection. Furthermore, for the main message of our
paper, i.e. the comparison of NPV- vs. best quartile-
based assessment of super-response, this aspect is of
subordinate importance as patients served as their own
controls. Overall, our findings are representative of cur-
rent daily practice for CRT, and should therefore be of
value for clinicians involved in the care of these patients.
Subgroup analyses (e.g., analyzing only patients with
sinus rhythm at implantation) were beyond the scope of
our study.
Conclusions
All cut-offs, independent of the method by which they were
assessed, were associated with a significant reduction in the
combined primary endpoint of all-cause death, heart
transplantation, ventricular assist device implantation, and
hospitalization for heart failure, as well as the secondary
endpoints (except LVEF C25 % for the mortality end-
point). Overall, the NPV-based method was not able to
more ‘‘accurately’’ define super-response to CRT than the
best quartile-based method comparing 5-years freedom
from endpoints. Importantly, NPV- and best quartile-based
cut-offs validate previously applied empirical
Fig. 3 Best quartile-based method: probability of freedom from the
combined endpoint (upper), death/heart transplantation/ventricular
assist device (middle) and hospitalization for heart failure (lower
panel) for different definitions of super-responder: D LVEF[14 %
(left); EDVI\25 % (middle) and ESVI\36 % (right)
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echocardiographic cut-offs to define super-response to
CRT and provide evidence for using these cut-offs in daily
practice, and to facilitate inter-study comparability.
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